Skip to main content
SpringerLink
Log in

Absence of apoptosis in somatotropinomas treated with octreotide

  • Clinical Articles
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Summary

Octreotide is a potent agonist of somatostatin that lowers the serum level of growth hormone (GH), and reduces the size of somatotropinomas. However, the detailed mechanism of shrinkage of this tumour is not known. We, therefore, evaluated 11 patients with somatotropinomas who were treated with octreotide 300 μg/day for 2–5 weeks to observe the morphological changes in the tumour using electron microscopy and the immunocytochemical study of apoptosis using polyclonal anti-single stranded DNA. Findings were compared with those obtained with bromocriptine treatment (10 mg/day, 2 weeks) of 5 patients with somatotropinomas, and 11 patients who received no preoperative treatment (control group).

The octreotide group showed neither increase in stromal tissue nor cell death. The size of tumour cells appeared to be slightly reduced. No typical apoptotic bodies were seen on the electron micrographs. The apoptotic index in the octreotide group (0.40 ± 0.60%; mean ± SD) resembled that in the control group (0.81 ± 0.79%). In contast, the bromocriptine group showed some cell death and an increase in stromal tissue. The bromocriptine group also showed the apoptotic index which (20.1 ± 14.8%) was significantly higher than that of the control group (0.81 ± 0.79%).

Thus, octreotide did not induce apoptosis in somatotropinomas despite the presence of tumour shrinkage. Because of the lack of fibrosis observed in the octreotide-treated tumours, the preoperative administration of octreotide may help to improve the outcome of the transsphenoidal operation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Kelch RP, Beitins IZ (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67: 1040–1048

    PubMed  Google Scholar 

  2. Davis DH, Laws Jr ER, Ilstrup DM, Speed JK, Caruso M, Shaw EG, Abboud CF, Scheithauer BW, Root LM, Schleck C (1993) Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg 79: 70–75

    PubMed  Google Scholar 

  3. Davis JRE, Wilson EM, Vidal ME, Johnson AP, Lynch SS, Sheppard MC (1989) Regulation of growth hormone secretion and messenger ribonucleic acid accumulation in human somatotropinoma cells in vitro. J Clin Endocrinol Metab 69: 704–708

    PubMed  Google Scholar 

  4. Drewett N, Jacobi JM, Willgoss DA, Lloyd HM (1993) Apoptosis in the anterior pituitary gland of the rat: Studies with estrogen and bromocriptine. Neuroendocrinology 57: 89–95

    PubMed  Google Scholar 

  5. Ekramullah SM, Saitoh Y, Ohnishi T, Arita N, Taki T, Hayakawa T (1995) Effects of bromocriptine on staining indices of Ki-67 and proliferating cell nuclear antigen, and nucleolar organizer region number in pituitary adenomas. Neurol Med Chir (Tokyo) 35: 221–226

    Google Scholar 

  6. Ezzat S, Horvath E, Harris AG, Kovacs K (1994) Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 79: 113–118

    PubMed  Google Scholar 

  7. Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493–501

    PubMed  Google Scholar 

  8. Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S (1984) Necrotic changes in prolactinomas after long term administration of bromocriptine. J Clin Endocrinol Metab 59: 463–470

    PubMed  Google Scholar 

  9. Gerdes J, Becker MHG, Key G (1992) Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissue. J Pathol 168: 85–87

    PubMed  Google Scholar 

  10. Kawamoto K, Uozumi T, Sakoda K, Mukada K, Kurisu K, Yano T (1992) Cytocidal effects of bromocriptine, somatostatin analog, and heat on growth hormone-secreting pituitary adenoma in vitro. Cancer 69: 2688–2696

    PubMed  Google Scholar 

  11. Keino H, Masaki S, Kawarada Y, Naruse I (1993) Apoptotic degeneration in the archinencephalic brain of the mouse mutant Pdn/Pdn. Dev Brain Res 78: 161–168

    Google Scholar 

  12. Kitagawa Y, Okuhara E (1981) Anti-poly(l)-poly(C) antibody bound to cellulose and its use in the specific separation of double-stranded RN As. Anal Biochem 115: 102–108

    PubMed  Google Scholar 

  13. Kovacs K, Stefaneanu L, Horvath E (1991) Effect of dopamine agonist medications on prolactin producing pituitary adenomas. Virchows Arch [Pathol Anat] 418: 439–446

    Google Scholar 

  14. Lamberts SWJ (1988) The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogues in the treatment of human pituitary tumours. Endocr Rev 9: 417–436

    PubMed  Google Scholar 

  15. Lucas-Morante T, Garcia-Uria J, Estrada J, Saucedo G, Cabello A, Alcañiz J, Barceló B (1994) Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 81: 10–14

    PubMed  Google Scholar 

  16. Maurer RA (1981) Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Nature 294: 94–97

    PubMed  Google Scholar 

  17. Melmed S, Dowling H, Frohman L, Ho K, Lamberts SWJ, Lamont JT, Sassolas G, Schoenfield L, Snyder PJ, Wass JAH (1994) Consensus statement: Benefits versus risks of medical therapy for acromegaly. Am J Med 97: 468–473

    PubMed  Google Scholar 

  18. Mori H, Hiromoto N, Nakahara M, Shiraishi T (1982) Stereological analysis of Leydig cell ultrastructure in aged humans. J Clin Endocrinol Metab 55: 634–641

    PubMed  Google Scholar 

  19. Mori H, Mori S, Saitoh Y, Arita N, Aono T, Uozumi T, Mogami H, Matsumoto K (1985) Effects of bromocriptine on prolactin-secreting pituitary adenomas: Mechanisms of reduction in tumour size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis. Cancer 56: 230–238

    PubMed  Google Scholar 

  20. Naruse I, Keino H, Kawarada Y (1994) Antibody against single-stranded DNA detects both programmed cell death and drag-induced apoptosis. Histochemistry 101: 73–78

    PubMed  Google Scholar 

  21. Pagliacci MC, Tognellini R, Grignani F, Nicoletti I (1991) Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: Effects on cell cycle parameters and apoptotic cell death. Endocrinology 129: 2555–2562

    PubMed  Google Scholar 

  22. Pelicci G, Pagliacci MC, Lanfrancone L, Pelicci PG, Grignani F, Nicoletti I (1990) Inhibitory effect of the somatostatin analog octreotide on rat pituitary tumour cell (GH3) proliferation in vitro. J Endocrinol Invest 13: 657–662

    PubMed  Google Scholar 

  23. Plescia JO (1964) Production of antibodies to denatured deoxyribonucleic acid. Proc Natl Acad Sci USA 52: 279–285

    PubMed  Google Scholar 

  24. Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe H-J (1994) Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumour volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79: 1416–1423

    PubMed  Google Scholar 

  25. Saitoh Y, Mori S, Arita N, Hayakawa T, Mogami H, Matsumoto K, Mori H (1986) Cytosuppressive effect of bromocriptine on human prolactinomas: Stereological analysis of ultrastructural alterations with special reference to secretory granules. Cancer Res 46: 1507–1512

    PubMed  Google Scholar 

  26. Saitoh Y, Mori S, Arita N, Hayakawa T, Mogami H, Ohta M, Uozumi T (1984) Results of transsphenoidal surgery for growth-hormone secreting adenomas. Neurol Med Chir (Tokyo) 24: 478–484

    Google Scholar 

  27. Shi SR, Key ME, Kalra KL (1991) Antigen retrieval in formalinfixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741–748

    PubMed  Google Scholar 

  28. Shibuya M, Saito F, Miwa T, Davis RL, Wilson CB, Hoshino T (1992) Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol 84: 178–183

    PubMed  Google Scholar 

  29. Stevenaert A, Harris AG, Kovacs K, Beckers A (1992) Presurgical octreotide treatment in acromegaly. Metabolism 41 [Suppl 2]: 51–58

    PubMed  Google Scholar 

  30. Taki T, Ohnishi T, Arita N, Hiraga S, Saitoh Y, Izumoto S, Mori K, Hayakawa T (1994) Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: Potent inhibition of tumour angiogenesis. J Neurooncol 19: 251–258

    PubMed  Google Scholar 

  31. Tomei L (1991) Apoptosis: a program for death or survival? In: Tomei LD, Cope FD (eds) Apoptosis. The molecular basis of cell death. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp 279–316

    Google Scholar 

  32. Vance ML, Harris AG (1991) Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicenter acromegaly study group. Arch Intern Med 151: 1573–1578

    PubMed  Google Scholar 

  33. Yamada H, Hirai S, Ikegami S, Kawarada Y, Okuhara E, Nagano H (1985) The fate of DNA originally existing in the zygote nucleus during achromosomal cleavage of fertilized echinoderm eggs in the presence of aphidicolin: Microscopic studies with anti-DNA antibody. J Cell Physiol 124: 9–12

    PubMed  Google Scholar 

  34. Yin D, Kondo S, Takeuchi J, Morimura T (1993) Induction of apoptosis in rat somatotrophin-secreting pituitary adenoma cells by bromocriptine. Oncol Res 5: 383–387

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Osaka University Medical School, Suita, Osaka

    Y. Saitoh, N. Arita, T. Ohnishi, S. Ekramullah & T. Hayakawa

  2. Department of Pathology, The Center for Adult Diseases, Higashinari, Osaka-City, Osaka, Japan

    K. Takemura

Authors
  1. Y. Saitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Arita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Ohnishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Ekramullah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Takemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Hayakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saitoh, Y., Arita, N., Ohnishi, T. et al. Absence of apoptosis in somatotropinomas treated with octreotide. Acta neurochir 139, 851–856 (1997). https://doi.org/10.1007/BF01411403

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01411403

Keywords

Search

Navigation